Corporate News     10-Apr-24
Dr Reddys launches migraine management wearable device Nerivio® in Germany

Dr. Reddy's Laboratories announced the launch of the drug-free non-invasive migraine management wearable device Nerivio® in Germany through its step-down subsidiary betapharm. The launch marks the company's entry into digital therapeutics in Europe. Nerivio® is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.

Nerivio® was presented in 2023 by Dr. Reddy's at the DGN Kongress organised by the German Association of Neurology in Berlin, and the 17th European Headache Congress held in Barcelona, Spain. Dr. Reddy's will present and launch Nerivio® during the Neurological Association of South Africa annual congress on April 17, 2024, in the presence of Dr. Stewart Tepper, Professor of Neurology at the Geisel School of Medicine – Dartmouth, and Vice President, New England Institute for Neurology and Headache. In May 2024, Nerivio® will also be presented at International Headache Society 2024 iHEAD meeting in Berlin, Germany. In subsequent months, Dr. Reddy's will launch Nerivio® in Spain and the UK.

Last year, Dr. Reddy's entered into an exclusive agreement with Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, for the marketing and distribution of Nerivio® in multiple markets.

Dr. Reddy's launched Nerivio® in India in 2023. In India, Nerivio® is supported by Dr. Reddy's unique patient support programme called ‘M-Free'. The programme is a comprehensive support system that enhances and streamlines the journey of the patients. M-Free includes services such as onboarding and counseling of patients, device demonstrations, doorstep delivery, flexible payment options, informative content, and dedicated customer care to help patients get the most out of the device. With lifestyle modification as a key recommendation for better management of migraine, M-Free awareness program offers a suite of value-add services such as nutritionist consultation, yoga and meditation sessions with certified specialists for holistic medicine free migraine management.

Previous News
  Dr Reddys Laboratories
 ( Results - Analysis 08-May-24   09:36 )
  Dr Reddy's Q4 PAT jumps 36% YoY to Rs 1,307 crore
 ( Hot Pursuit - 07-May-24   17:26 )
  Dr Reddy's Laboratories consolidated net profit rises 36.42% in the March 2024 quarter
 ( Results - Announcements 07-May-24   16:59 )
  Dr Reddys Laboratories AGM scheduled
 ( Corporate News - 07-May-24   16:41 )
  Board of Dr Reddys Laboratories recommends final dividend
 ( Corporate News - 07-May-24   16:41 )
  Dr Reddy's Labs launches generic Oracea capsules in US markets
 ( Hot Pursuit - 06-May-24   09:29 )
  Dr Reddy's launches Doxycycline Capsules in the US
 ( Corporate News - 03-May-24   15:50 )
  Nestle India and Dr Reddy's to form JV focused on nutritional health solutions
 ( Corporate News - 25-Apr-24   12:56 )
  Dr. Reddy's launches condition management programme DailyBloom™ IBS
 ( Corporate News - 19-Apr-24   16:08 )
  Market at day's low; Nifty slides below 22,600
 ( Market Commentary - Mid-Session 12-Apr-24   13:31 )
  Dr. Reddy’s Lab arm launches migraine management device, Nerivio in Europe
 ( Hot Pursuit - 11-Apr-24   13:35 )
Other Stories
  Fortis Healthcare announces board meeting date
  17-May-24   14:57
  Dhani Services to convene board meeting
  17-May-24   14:57
  Rupa & Company declare Quarterly Result
  17-May-24   14:57
  FCS Software Solutions to hold board meeting
  17-May-24   14:56
  Advance Petrochemicals to table results
  17-May-24   14:56
  Trinity League India to discuss results
  17-May-24   14:56
  Amraworld Agrico announces board meeting date
  17-May-24   14:56
  Board of Shetron recommends Final Dividend
  17-May-24   14:49
  Board of GPT Infraprojects recommends Third Interim Dividend
  17-May-24   14:48
  Board of Indraprastha Medical Corporation recommends Final Dividend
  17-May-24   14:48
Back Top